September 14, 2026
The United States has long been the largest medical technology market in the world. But today, that distinction comes with a hiring problem that many commercial leaders are only beginning to reckon with.
The US now accounts for over 45% of global medtech revenue. Surgical procedure volumes hit 95.7 million in 2024 — revised upward from earlier projections — and are expected to reach 97.8 million by the end of 2025, with the 100-million milestone anticipated by 2026 or 2027. Meanwhile, Software as a Medical Device is growing at 24.3% annually, and M&A activity in the sector reached 65 transactions totaling $21.7 billion in Q3 2025 alone — the most active quarter since 2022.
All of that growth is generating commercial hiring demand at a pace the talent market simply cannot match. And because the US concentrates so much of that activity into a handful of innovation hubs — California, Massachusetts, Minnesota, and Texas — the competition for proven commercial talent in those geographies is as acute as it has ever been.
For hiring managers in MedTech, the old playbook is no longer adequate. Here is what is driving the pressure, and what needs to change.
A MedTech commercial role in 2026 is not the same position it was five years ago. Products have grown significantly more complex — AI-enabled diagnostics, robotic-assisted surgery, and Software as a Medical Device solutions are now core commercial priorities, not future roadmap items. Selling these products requires more than clinical credibility. It demands data literacy, fluency across hospital IT systems, and the ability to communicate value across buying committees that now include supply chain managers, finance directors, IT administrators, and value analysis teams alongside clinical stakeholders.
At the same time, many MedTech companies are transitioning away from transactional sales models toward recurring revenue structures — subscriptions, leasing arrangements, and blended bundles. That shift changes what a high-performing commercial hire looks like. The candidate who exceeded quota selling capital equipment under a straightforward purchase model may not be the right profile for an account that requires long-term relationship management, usage data interpretation, and renewal conversations.
The candidate pool that fits this evolved role is genuinely small. And every MedTech company in the country is looking for the same person.
The broader hiring data reflects this gap. Research from Skills Alliance found that 38% of MedTech organizations cite wage competition as their single largest hiring challenge, while 29% point to the length of their own recruitment processes as a primary obstacle. Only 21% of organizations report a limited candidate pool — which suggests that most hiring managers still believe the talent is out there, even as their time-to-fill numbers tell a different story.
Deloitte's research adds a longer-horizon dimension: the sector is projected to face a global talent shortage of 4.3 million people by 2030. Critically, their findings show that 75% of MedTech early adopters — companies already pulling ahead of the market — prioritize hiring digital expertise, compared to just 31% of laggards. The gap is not between companies that want good commercial talent and companies that do not. It is between companies that have adapted their hiring approach and those still running the same search they ran three years ago.
The M&A activity reshaping the sector is not just creating growth — it is also displacing experienced commercial talent and reshuffling territories in ways that make the market harder to read. When two established players merge, the resulting integration often produces commercial team redundancies. Talented professionals land back on the market briefly, but they are typically absorbed quickly, often before a standard recruitment process can reach them. Companies that rely on passive candidate pipelines built over time are better positioned to move fast. Companies that only start searching when a position opens are not.
One of the most common and costly mistakes in MedTech commercial hiring is an internally unclear role definition that generates a job description written around what the last person did — not what the business actually needs now. If the product portfolio has shifted to include SaMD or AI-enabled tools, the job description needs to reflect that. If the go-to-market model has changed, the seniority and profile requirements need to change with it.
Before writing the JD, the hiring manager, commercial leadership, and HR or talent acquisition should align on three things: what does success look like at 12 months, what is the primary buyer profile this person will engage, and what skills are genuinely non-negotiable versus trainable. That clarity produces a more defensible shortlist and shortens the overall process.
Many MedTech commercial teams still weight quota attainment in legacy product lines as the primary measure of a candidate's ceiling. That benchmark is increasingly unreliable for predicting performance in today's environment. A rep who exceeded targets selling a single-SKU capital device under a consultant-driven purchase process may be poorly equipped for a digital health solution requiring multi-stakeholder alignment and a longer, consultative sales cycle.
The evaluation framework needs updating. Structured behavioral interviews that probe for examples of multi-stakeholder selling, data-informed account strategy, and consultative problem-solving are a more accurate signal for the type of commercial talent the market now demands.
Wage competition is cited by 38% of MedTech organizations as their top hiring challenge — yet compensation benchmarking in many companies still trails the market by a cycle or two. In high-competition geographies, top commercial candidates have multiple active conversations, and they know what they are worth. An offer that would have closed a hire 18 months ago may be declined today — not because the candidate is unreasonable, but because the market has moved and the compensation band has not.
Compensation benchmarking should be refreshed at the start of every search, not carried forward from the previous headcount approval. For senior commercial hires particularly, the total package — base, variable structure, equity or long-term incentives, and flexibility — needs to be competitive with what PE-backed mid-market companies are now offering to attract VP and Director-level talent.
Twenty-nine percent of MedTech organizations identify the length of their own recruitment process as a primary hiring obstacle. In a market where strong commercial candidates are interviewing with three or four companies simultaneously, a slow process is not neutral — it is a competitive disadvantage. Every week of additional interview stages or delayed feedback is time that another company can use to make an offer.
The solution is not to compress due diligence. It is to run a process that is structured tightly enough to reach a decision in three to four interview touchpoints, with feedback exchanged between stages within 48 hours. Companies that have built this discipline into their hiring process consistently close stronger hires than those that treat urgency and rigor as competing values.
The MedTech companies best positioned for commercial hiring in 2026 are not the ones reacting to open roles — they are the ones that have been building relationships with relevant talent continuously, including candidates who were not immediately available. In high-competition geographies, the difference between a six-week fill and a five-month fill often comes down to whether a hiring manager had a conversation with the right person six months earlier.
This is where a specialist recruitment partner adds material value beyond sourcing. An experienced MedTech commercial recruiter maintains active relationships with candidates who are performing well in current roles, understands what would prompt them to move, and can make a credible, timely introduction when a position opens. That pipeline access is not replicable with a LinkedIn job posting and a reactive search.
The US MedTech market is growing — in revenue, in procedure volume, in M&A activity, and in technological complexity. None of those trends are reversing. What that means for commercial hiring is that the conditions driving today's talent competition are structural, not cyclical.
Hiring managers who treat this as a temporary tightening and wait it out will find themselves competing for a smaller share of the available pool. Those who take a hard look at how their role definitions, evaluation criteria, compensation frameworks, and process timelines compare to best practice will be the ones who build high-performing commercial teams in this environment.
The talent is in the market. The question is whether your hiring process is equipped to find it, evaluate it fairly, and move quickly enough to secure it.
If your MedTech commercial team has open roles you're struggling to fill, or if you're anticipating growth and want to build your talent strategy ahead of demand, speak with 44 International. Our specialist recruiters work exclusively across life sciences and MedTech commercial hiring in the US market.
Why this topic matters now:
The US MedTech sector is in a period of simultaneous expansion and structural change. Market revenue growth, M&A consolidation, the commercialization of AI-enabled products, and the expansion of ambulatory surgical centers are all increasing demand for experienced commercial talent at the same time that the skill requirements for those roles are changing substantially. The result is a market where experienced commercial professionals are in short supply relative to demand, and where companies running traditional hiring processes are consistently slower and less successful than those that have adapted.
The convergence of 65 M&A transactions totaling $21.7 billion in a single quarter, surgical procedure volume projections crossing 97.8 million in 2025, and SaMD growing at 24.3% annually provides a current, data-supported rationale for why this topic is urgent for MedTech commercial leaders in 2026. The hiring manager–focused angle — addressing what organizations should do differently rather than simply describing the problem — also aligns with 44 International's positioning as a specialist adviser, not just a recruiter.
© All rights reserved